Acquired endocrine resistance in breast cancer: implications for tumour metastasis
Acquired endocrine resistance in breast cancer: implications for tumour metastasis
复制标题
DOI：
10.2741/3723
复制
发表时间：
2011-01-01
影响因子：
3.1
通讯作者：
Hiscox, Stephen
中科院分区：
文献类型：
--
作者：
Hayes, Edd;Nicholson, Robert I.;Hiscox, Stephen
内分泌治疗是激素受体阳性乳腺癌的首选治疗方法。然而，这些药物的有效性受到耐药性发展的限制，最终导致疾病进展和患者死亡。虽然获得性内分泌耐药的临床前细胞模型已经证明了生长因子信号改变在内分泌不敏感表型发展中的作用，但越来越明显的是，乳腺癌中获得性内分泌耐药也伴随着不良细胞表型的发展，耐药细胞表现出改变的粘附相互作用，增强的迁移和侵袭行为。以及诱导内皮细胞血管生成反应的能力。由于癌细胞的侵袭和转移是乳腺癌患者死亡的主要原因，阐明伴随获得性内分泌抵抗及其后续靶向的不良细胞特征的分子机制可能提供一种限制此类肿瘤在体内进展的方法。
Endocrine therapy is the treatment of choice in hormone receptor-positive breast cancer. However, the effectiveness of these agents is limited by the development of drug resistance, ultimately leading to disease progression and patient mortality. Whilst pre-clinical cell models of acquired endocrine resistance have demonstrated a role for altered growth factor signalling in the development of an endocrine insensitive phenotype, it is becoming apparent that acquisition of endocrine resistance in breast cancer is also accompanied by the development of an adverse cellular phenotype, with resistant cells exhibiting altered adhesive interactions, enhanced migratory and invasive behaviour, and a capacity to induce angiogenic responses in endothelium. Since invasion and metastasis of cancer cells is a major cause of mortality in breast cancer patients, elucidation of molecular mechanisms underlying the adverse cellular features that accompany acquired endocrine resistance and their subsequent targeting may provide a means of limiting the progression of such tumours in vivo.